A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

NCT01904279 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche